object
purpos
present
studi
appli
revers
transcriptionpcr
rtpcr
assay
clinic
specimen
collect
patient
acut
respiratori
ill
chronic
obstruct
pulmonari
diseas
copd
method
one
hundr
ninetyfour
sampl
two
differ
studi
cohort
analys
use
rtpcr
assay
picornavirus
coronavirus
influenza
b
virus
respiratori
syncyti
viru
parainfluenza
type
virus
human
metapneumoviru
pcr
assay
adenovirus
result
ad
result
obtain
previous
use
cell
cultur
serolog
method
result
rtpcr
assay
identifi
addit
respiratori
virusassoci
ill
identifi
previous
cell
cultur
serolog
picornavirus
coronavirus
common
viral
infect
identifi
rtpcr
overal
acut
respiratori
ill
evalu
associ
respiratori
viru
infect
picornavirus
coronavirus
influenza
virus
common
infect
recogn
human
metapneumoviru
infect
identifi
rtpcr
assay
conclus
respiratori
viral
infect
commonli
associ
acut
respiratori
ill
copd
patient
use
rtpcr
assay
significantli
increas
abil
diagnos
infect
fourth
common
caus
death
unit
state
chronic
lower
respiratori
diseas
journal
infect
patient
chronic
obstruct
pulmonari
diseas
copd
also
suffer
recurr
exacerb
increas
morbid
diseas
contribut
mortal
acut
exacerb
copd
associ
acut
infect
respiratori
tract
caus
bacteria
virus
bacteria
virus
frequenc
respiratori
viru
infect
identifi
associ
acut
worsen
respiratori
function
patient
copd
vari
differ
studi
previous
perform
two
studi
evalu
preval
acut
respiratori
viral
infect
patient
includ
copd
studi
util
cell
cultur
serolog
method
identifi
acut
respiratori
viru
infect
studi
examin
frequenc
specif
respiratori
viru
infect
person
acut
respiratori
tract
condit
lead
hospit
studi
longitudin
cohort
copd
patient
test
rtvi
ambulatori
set
although
patient
also
hospit
respiratori
viral
infect
identifi
copd
subject
acut
respiratori
ill
reversetranscript
polymeras
chain
reaction
rtpcr
assay
identifi
respiratori
viru
infect
miss
cell
cultur
number
respiratori
viral
infect
identifi
asthmat
patient
acut
exacerb
diseas
increas
significantli
rtpcr
assay
use
addit
diagnost
method
similar
observ
made
acut
exacerb
copd
order
extend
understand
preval
respiratori
viral
infect
acut
respiratori
ill
patient
copd
use
rtpcr
assay
evalu
sampl
previou
two
prospect
studi
evid
respiratori
viru
infect
materi
method
patient
copd
enrol
two
prospect
clinic
studi
design
identifi
respiratori
virus
associ
exacerb
lung
diseas
studi
evalu
preval
rtvi
among
patient
hospit
admit
diagnosi
acut
respiratori
ill
congest
heart
failur
juli
june
patient
identifi
review
admiss
log
person
exacerb
copd
enrol
studi
identifi
use
discharg
diagnosi
code
code
studi
longitudin
studi
conduct
septemb
may
evalu
incid
rtvi
cohort
patient
copd
criteria
diagnosi
copd
defin
american
thorac
societi
exacerb
copd
defin
meet
one
criteria
anthonisen
et
al
increas
dyspnoea
sputum
product
sputum
purul
rtvi
studi
identifi
viru
cultur
combin
nasal
washthroat
swab
specimen
serolog
assay
previous
describ
evalu
avail
sampl
collect
septemb
june
use
analysi
combin
nasal
washthroat
swab
sampl
transport
laboratori
wet
ice
inocul
onto
cell
cultur
usual
within
h
store
prior
perform
viral
rtpcr
assay
microneutr
assay
use
measur
antibodi
level
influenza
b
virus
respiratori
syncyti
viru
parainfluenza
type
virus
coronaviru
hemagglutin
inhibit
assay
also
use
measur
influenza
b
viru
antibodi
enzymelink
immunosorb
assay
elisa
use
measur
antibodi
coronaviru
rtpcr
studi
follow
rtpcr
pcr
assay
limit
detect
use
assay
clinic
specimen
follow
influenza
b
virus
tissu
cultur
infecti
dose
tcid
respiratori
syncyti
viru
tcid
parainfluenza
viru
type
tcid
coronaviru
tcid
picornavirus
tcid
adenovirus
tcid
human
metapneumoviru
tcid
tabl
assay
consist
three
major
step
nucleic
acid
extract
complementari
dna
cdna
synthesi
amplif
rtpcr
identif
virusspecif
amplicon
southern
blot
hybrid
nucleic
acid
extract
nasal
washthroat
swab
sampl
use
viral
rna
mini
kit
qiagen
inc
valencia
ca
accord
manufactur
instruct
rtpcrpcr
assay
perform
previous
describ
use
primer
list
tabl
detect
human
metapneumoviru
infect
cdna
synthes
h
initi
heat
denatur
cycl
heat
denatur
anneal
primer
extens
iia
aat
tgc
tii
tct
tgt
tct
virusspecif
pcr
product
detect
southern
hybrid
use
digoxigeninlabel
probe
see
tabl
human
metapneumovirusspecif
amplim
identifi
follow
hybrid
virusspecif
digoxigeninlabel
oligoprob
realtim
rtpcr
assay
also
perform
influenza
b
virus
coronaviru
virus
influenza
virusspecif
assay
perform
previous
describ
coronavirusspecif
assay
cdna
gener
singl
reaction
thermal
cycler
h
specimen
assay
duplic
ml
reaction
contain
ml
taqman
univers
pcr
master
mix
appli
biosystem
foster
citi
ca
ml
cdna
nm
forward
revers
primer
nm
fluorogen
probe
amplif
detect
perform
use
geneamp
sequenc
detect
system
appli
biosystem
follow
condit
min
denatur
follow
cycl
min
extract
reagent
posit
neg
control
use
experi
assur
valid
experiment
result
step
prevent
carryov
contamin
use
routin
separ
sampl
prepar
separ
pcr
setup
postpcr
analysi
area
use
plug
pipett
tip
traffic
control
clean
prepcr
dirti
postpcr
area
use
extract
reagent
posit
neg
control
assay
consid
valid
neg
control
yield
neg
result
posit
control
yield
posit
result
studi
subject
separ
ill
sampl
avail
analysi
tabl
particip
studi
younger
vs
year
like
nonwhit
vs
p
less
like
receiv
influenza
vaccin
vs
p
studi
major
subject
studi
smoke
histori
larger
percentag
person
studi
still
smoke
studi
enrol
vs
p
pair
sera
avail
analysi
fewer
ill
studi
studi
vs
p
eightyeight
respiratori
viral
infect
identifi
ill
two
studi
seven
ill
dual
respiratori
infect
identifi
tabl
fifti
infect
identifi
cultur
serolog
method
rtpcr
assay
identifi
addit
infect
overal
picornavirus
rhinovirus
enterovirus
common
respiratori
viru
infect
identifi
frequent
viru
group
identifi
rtpcr
twentyeight
isol
picornavirus
classifi
genu
level
rhinovirus
enterovirus
influenza
virus
coronavirus
next
commonli
identifi
virus
fourteen
influenza
viru
infect
caus
influenza
virus
influenza
viru
infect
common
studi
none
influenza
virusinfect
subject
document
receiv
influenza
vaccin
prior
year
twelv
coronaviru
infect
identifi
caus
strain
one
four
infect
strain
occur
hospit
subject
four
infect
identifi
rtpcr
parainfluenza
viru
infect
occur
less
ill
two
two
five
parainfluenza
viru
infect
seen
type
strain
respect
rtpcr
identifi
two
addit
type
infect
one
addit
type
infect
rsv
infect
studi
studi
studi
realtim
pcr
assay
seen
subject
addit
rsv
infect
identifi
rtpcr
rtpcr
assay
use
identifi
human
metapneumoviru
infect
infect
viru
identifi
fifteen
respiratori
ill
studi
upper
respiratori
ill
manag
outpati
set
eighti
percent
ill
associ
respiratori
viral
infect
compar
acut
exacerb
copd
studi
six
picornaviru
four
coronaviru
two
parainfluenza
viru
one
influenza
viru
one
rsv
infect
two
dual
associ
common
cold
ill
applic
rtpcr
assay
clinic
specimen
collect
patient
copd
acut
respiratori
ill
significantli
increas
number
ill
associ
respiratori
viral
infect
identifi
cultur
serolog
studi
use
viru
identif
sampl
ill
associ
respiratori
viru
infect
addit
rtpcr
assay
increas
overal
percentag
respiratori
virusassoci
ill
similar
patient
seemung
et
al
note
respiratori
viru
infect
associ
acut
exacerb
copd
somewhat
lower
preval
rate
rohd
et
al
note
copd
patient
hospit
acut
exacerb
report
seemung
et
al
later
studi
percentag
dual
respiratori
infect
also
similar
rate
report
previou
studi
picornavirus
coronavirus
like
viral
pathogen
detect
use
rtpcr
assay
picornaviru
infect
especi
caus
rhinovirus
preval
respiratori
viru
infect
identifi
copd
patient
acut
respiratori
ill
recent
studi
mani
rhinovirus
grow
poorli
cell
cultur
detect
rtpcr
assay
use
similarli
coronavirus
either
difficult
grow
grow
use
current
cell
cultur
method
surpris
number
infect
identifi
increas
applic
rtpcr
techniqu
coronavirus
associ
viral
ill
copd
patient
rtpcr
assay
use
influenza
viru
remain
import
caus
viru
infect
copd
patient
especi
hospit
patient
fifteen
ill
studi
associ
influenza
viru
infect
compar
four
studi
less
half
patient
studi
receiv
influenza
vaccin
previou
year
almost
patient
studi
accept
influenza
vaccin
time
frame
use
influenza
vaccin
safe
effect
recommend
popul
nevertheless
lack
use
influenza
vaccin
persist
modifi
risk
factor
patient
hospit
copd
respiratori
syncyti
viru
increasingli
recogn
import
viral
pathogen
older
adult
ill
evalu
two
studi
associ
rsv
infect
number
similar
observ
studi
lower
report
other
differ
method
use
identifi
rsv
infect
differ
sensit
rtpcr
assay
like
contribut
differ
observ
studi
human
metapneumoviru
newli
recogn
paramyxoviru
caus
lower
respiratori
diseas
children
import
pathogen
adult
less
well
defin
falsey
et
al
found
subject
admit
acut
cardiopulmonari
condit
serolog
evid
acut
human
metapneumoviru
infect
preval
rate
somewhat
lower
ambulatori
geriatr
popul
consider
variabl
two
studi
year
case
human
metapneumoviru
infect
also
observ
elderli
patient
hospit
chronic
lower
respiratori
diseas
immunosuppress
contrast
fail
identifi
ill
associ
human
metapneumoviru
infect
rtpcr
assay
human
metapneumoviru
design
detect
known
group
human
metapneumoviru
detect
virus
anoth
studi
involv
hospit
children
unpublish
data
differ
assay
perform
could
explain
result
observ
altern
viru
circul
season
studi
may
low
enough
prevent
detect
potenti
weak
studi
evalu
impact
respiratori
virus
two
popul
time
clinic
stabil
seemung
et
al
report
detect
respiratori
virus
rsv
copd
patient
clinic
stabil
detect
rsv
recent
complet
evalu
anoth
cohort
chronic
bronchit
patient
period
clinic
stabil
unpublish
data
preval
rtpcr
posit
exclud
coronaviru
human
metapneumoviru
rang
individu
agent
overal
preval
encount
overal
frequenc
identif
respiratori
viral
infect
ill
similar
seen
studi
thu
experi
applic
rtpcr
assay
cohort
copd
differ
describ
seemung
et
al
summari
applic
rtpcr
assay
clinic
specimen
collect
patient
copd
clinic
respiratori
ill
significantli
increas
number
respiratori
virus
identifi
rhinovirus
coronavirus
influenza
virus
common
respiratori
viru
infect
patient
popul
human
metapneumoviru
infect
found
respiratori
viru
infect
import
caus
respiratori
ill
copd
patient
health
research
grant
glaxosmithklin
